ConductScience.org, home
PARP12: poly(ADP-ribose) polymerase family member 12
API referenceFor AI assistants

Gene · 64761

Papers1,639

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 1,639

Download this page as JSON
TitleJournalYearPMIDFound bySource
XYL-1 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Suppressing the SCD1/BRCA1 Signaling Pathway.Molecules202642653863PubTator, text miningPubMed
Beyond Catalytic Inhibition: The Evolving Landscape of PARP Pharmacology.Annu Rev Pharmacol Toxicol202642574757PubTator, text miningPubMed
From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.Front Oncol202642568603PubTator, text miningPubMed
Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy.ACS Chem Biol202642504699PubTator, text miningPubMed
PARP1 as a Central Node in DNA Repair and Epigenetic Regulation: Implications for Biomarker Discovery and Targeted Therapy in NSCLC.Mini Rev Med Chem202642474024PubTator, text miningPubMed
FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability.Nat Commun202642380136PubTator, text miningPubMed
Selective biological activity of parthenolide derivatives - stizolin, stizolicin, and izospiciformin - isolated from the leaves of Stizolophus balsamita, in different breast cancer molecular subtypes in vitro.
Front Pharmacol202642199856PubTator, text miningPubMed
PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer.Front Immunol202642148103PubTator, text miningPubMed
Unraveling the pyroptosis pathway: Key insights into methotrexate-induced liver injury.Biochem Pharmacol202642140447PubTator, text miningPubMed
A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients.Cancers (Basel)202642122217PubTator, text miningPubMed
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.Br J Cancer202642092176PubTator, text miningPubMed
Crosstalk between integrin signaling and NAD⁺ biosynthetic pathways promotes glycolysis, proliferation, survival, and tumor growth in triple-negative breast cancer.Oncogene202642056559PubTator, text miningPubMed
PARP14 as a master regulator of immune signaling and tumor microenvironment remodeling.Biochem Pharmacol202642034313PubTator, text miningPubMed
Elevated proportion of BST2 + CD4 + T cells: a potential biomarker for diagnosis and disease activity in Sjögren's disease.Clin Rheumatol202641954819PubTator, text miningPubMed
The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential.J Med Virol202641910366PubTator, text miningPubMed
Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.Molecules202641900138PubTator, text miningPubMed
PARG inhibition sequesters nuclear PAR-binding proteins, including XRCC1 and its partners, into nuclear condensates to elicit cytotoxicity.bioRxiv202641890038PubTator, text miningPubMed
Silencing RPL9 promotes malignant proliferation in breast cancer cells.Int J Immunopathol Pharmacol202641877589PubTator, text miningPubMed
Recent Advances in Targeted Therapies for Adult Gliomas.Curr Neurol Neurosci Rep202641874881PubTator, text miningPubMed
Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy.Cell Death Dis202641862449PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/64761/papers

API referenceFor AI assistants